Keratoconus News and Research

RSS

Avedro submits VibeX/KXL System NDA with FDA to treat keratoconus, corneal ectasia

Avedro, Inc. announced today that the Company submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for its VibeX (riboflavin ophthalmic solution) /KXL System for the treatment of keratoconus and corneal ectasia following refractive surgery.

9 Mar 2012

Collagen crosslinking for keratoconus may receive FDA approval in 2012

Patients in the United States who have the cornea-damaging disease keratoconus may soon be able to benefit from a new treatment that is already proving effective in Europe and other parts of the world.

24 Oct 2011

Avedro acquires proprietary and patent pending transepithelial ParaCel riboflavin formulation

Avedro, Inc announced today that it has acquired all the intellectual property rights to produce, market, and distribute a breakthrough transepithelial riboflavin formulation based on the research of Roberto Pinelli, MD at the Istituto Laser Microchirurgia Oculare (ILMO) in Brescia, Italy.

14 Sep 2011

FDA grants orphan drug designation for Avedro's VibeX to treat Keratoconus

Avedro, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's VibeX for use with its KXL System (UVA irradiation) for Corneal Cross-linking to treat Keratoconus.

12 Sep 2011

Avedro receives Gold MDEA award for Vedera System

Avedro, Inc. announced today that the Vedera System for performing Keraflex has received the prestigious Gold level 2011 Medical Design Excellence Award.

22 Jun 2011

$Avedro completes two Phase III corneal cross-linking studies in keratoconus, ectasia post-refractive surgery$

Avedro completes two Phase III corneal cross-linking studies in keratoconus, ectasia post-refractive surgery

Avedro, Inc. today announced the completion of all one-year follow-up visits for patients enrolled in its two multi-center Phase III studies evaluating the safety and efficacy of corneal collagen cross-linking for the treatment of progressive keratoconus and ectasia following refractive surgery.

18 May 2011

Paulig Eye Surgery Center provides non-invasive alternative to keratoconus patients

The Paulig Eye Surgery Centre announces today that it has acquired advanced technology for performing Keraflex KXL, a new, non-invasive, non-surgical treatment for keratoconus. Surgeons at the Paulig Eye Surgery Centre will immediately begin treating patients using Avedro, Inc's Keraflex and KXL Systems.

3 May 2011

Avedro's KXL System for corneal cross-linking granted European CE Mark

Avedro, Inc., sponsor of two completed US FDA multi-center clinical trials for corneal cross-linking, today announced that its KXL™ System for performing accelerated corneal cross-linking (KXL) has received the European Union's CE Mark. The CE Mark certifies that the KXL System has met the EU's health and safety standards and opens the door to immediate commercialization across the European Economic Community and in other countries recognizing the CE Mark.

17 Nov 2010

Cornea and Laser Eye Institute to study CXL effectiveness in keratoconus patients

The Cornea and Laser Eye Institute, with Principal Investigator, Peter S. Hersh M.D., is conducting a research study to study the safety and effectiveness of corneal collagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin in patients with progressive keratoconus and corneal ectasia.

17 Sep 2010

Researchers show biosynthetic cornea can stimulate regeneration in damaged eye tissue

A new study from researchers in Canada and Sweden has shown that biosynthetic corneas can help regenerate and repair damaged eye tissue and improve vision in humans.

26 Aug 2010

Avedro to acquire Corneal Collagen Crosslinking Phase III study rights from Peschke Meditrade

Avedro, Inc. today announced it has signed a definitive agreement with Swiss-based Peschke Meditrade GmbH to acquire the rights to its Phase III studies of Corneal Collagen Crosslinking for the treatment of progressive keratoconus and post LASIK ectasia. The two randomized, controlled, multi-site clinical trials are designed to assess the safety and efficacy of riboflavin/ultraviolet-A light for halting the progression of these degenerative disorders and the accompanying decline in patient’s visual acuity.

17 Mar 2010

Renowned ophthalmologist performs innovative procedure on patient suffering from severe visual impairment

Ten years ago, Southern Californian resident Kenny Atkins suffered from severe visual impairment caused by coning of the cornea, otherwise known as keratoconus. Prescription glasses and contact lenses proved to be ineffective, and Atkins needed a solution fast – as an ocean lifeguard, Atkins’ ability to see could mean the difference between life and death.

6 Jan 2010

SynergEyes wins the 22nd annual Most Innovative New Product Award for 2009

CONNECT(R), one of the nation's most successful organizations dedicated to creating and sustaining the growth of innovative technology and life science businesses, announced SynergEyes, Inc., the high Dk hybrid contact lens manufacturer, as the winner of its 22nd annual Most Innovative New Product (MIP) Award for 2009.

22 Dec 2009

Encouraging early clinical results for treatment of KC with Avedro's Keraflex KXL technology

During the 5th International Congress of Corneal Cross Linking for Keratoconus in Leipzig, Germany on December 5th, Avedro presented encouraging early clinical results for treating keratoconus, a progressive disease of the cornea of the eye. The procedure, known as Keraflex® KXL, is non-incisional and reshapes the cornea without removing any tissue.

16 Dec 2009

CONNECT announces the winners of MIP Awards

CONNECT, one of the nation's most successful regional economic development programs for high technology and life science innovators, today announced the winners of the 22nd Annual Most Innovative New Product (MIP) Awards.

11 Dec 2009

Brandeis University researchers appraises economic benefits of BOS-P lens

Today, in the December issue of the American Journal of Ophthalmology Brandeis University researchers published a paper appraising the economic benefits of the BOS-P, a highly precise scleral lens used to treat severe cornea or ocular surface disease. A companion paper on the clinical benefits has been published online and will appear in the journal's January issue.

3 Dec 2009

Dr. Paul Cutarelli, the first ophthalmologist to implant an advanced nanoFLEX lens

A Denver ophthalmologist recently became the first in Colorado to implant a special type of lens during cataract surgery, raising the bar for patient care in the state while increasing the quality of life for his patients.

27 Oct 2009

Keratoconus patients to benefit from new contact lens launched by SynergEyes

SynergEyes, Inc., the high Dk hybrid contact lens manufacturer, recently introduced a new advanced lens design for keratoconus patients. ClearKone(TM) is a revolutionary contact lens that takes advantage of the best features of the hybrid platform, providing superior visual acuity, centration, stability, and all-day comfort.

5 Sep 2009

Study evaluates corneal collagen cross-linking in subjects with progressive keratoconus

Presently keratoconus is treated through eyeglasses, hard contact lenses, and a newer treatment, INTACS plastic rings inserted into the mid layer of the cornea to flatten it, changing the shape and location of the cone.

26 Nov 2008

Advances in ophthalmology

The 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE), the largest and most comprehensive ophthalmic educational meeting in the world, is in session November 8 to 11 at the Georgia World Congress Center, Atlanta.

10 Nov 2008